Streptozocin-treated Verner-Morrison Syndrome: plasma vasoactive intestinal peptide and tumor responses.
A patient with watery diarrhea, hypokalemia, hypochlorhydria, and a non-beta islet cell carcinoma of the pancreas (Verner-Morrison syndrome) was found to have an elevated vasoactive intestinal peptide (VIP) concentration in the plasma as well as in the tumor. Treatment with streptozocin resulted in a dramatic subjective and objective tumor response in this patient. Plasma VIP concentration fell into the normal range after four courses of treatment, diarrhea ceased after the third course of therapy, and measurable tumor mass markedly decreased during that same period of time. The patient remains in clinical remission with no evidence of tumor regrowth 18 months after the beginning of treatment. In this patient, plasma VIP measurements were an excellent marker of tumor activity and correlated well with objective disease measurements and clinical response.
D007516:Adenoma, Islet Cell / Q000188:drug therapy* / Q000648:ultrastructure; D003967:Diarrhea / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007008:Hypokalemia / Q000188:drug therapy*; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000648:ultrastructure; D013272:Stomach Diseases / Q000188:drug therapy*; D013311:Streptozocin / Q000627:therapeutic use*; D013577:Syndrome; D014660:Vasoactive Intestinal Peptide / Q000097:blood / Q000502:physiology
D014660:Vasoactive Intestinal Peptide; D013311:Streptozocin